Elsevier

Brain Research

Volume 800, Issue 2, 3 August 1998, Pages 319-322
Brain Research

Short communication
Effect of aminoguanidine on optic nerve involvement in experimental diabetic rats

https://doi.org/10.1016/S0006-8993(98)00512-5Get rights and content

Abstract

The effect of aminoguanidine (AG) on structural abnormalities in optic nerve fibers was evaluated in streptozotocin-induced diabetic rats. Morphometry of myelinated optic nerve fibers showed a partial amelioration on the reduction of the axon size but complete preservation of myelin size with low dose (25 mg kg−1 body weight) AG treatment. High dose (100 mg kg−1 body weight) AG completely prevented myelinated nerve fiber atrophy. These findings indicated that nonenzymatic glycation contributes to the development of optic nerve changes in diabetic rats.

Section snippets

Acknowledgements

This study was supported by Grant-in-Aid 07671918 from the Ministry of Education, Science and Culture, Japan. The authors wish to thank Miss Na-omi Kurumaya, Mr. Hiroaki Naka and Mr. Hiroshi Kuriyama for their support during this experiment. The secretarial assistance of Miss Chinatsu Inotani is also acknowledged.

References (31)

  • J.A. Corbett et al.

    Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction

    Diabetes

    (1992)
  • N.A. Cullum et al.

    Glycation of rat sciatic nerve tubulin in experimental diabetes mellitus

    Diabetologia

    (1991)
  • P.J. Dyck et al.

    Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy

    Ann. Neurol.

    (1986)
  • H.L. Federoff et al.

    Nonenzymatic glycation of laminin and laminin peptide CIKVAVS inhibits neurite outgrowth

    Diabetes

    (1993)
  • D.A. Greene et al.

    Complications: neuropathy, pathogenetic considerations

    Diabetes Care

    (1992)
  • Cited by (27)

    • Microstructure abnormity in the optic nerve of type 1 diabetic rats revealed by diffusion tensor imaging study

      2020, Magnetic Resonance Imaging
      Citation Excerpt :

      Besides, optic nerve atrophy may take partial role in the prolonged latencies of VEP [10]. In the isolated optic nerve of diabetic animals, axonal degeneration has been detected to be a primary pathological event [10–15]. However, due to the limitation of techniques, there are little clinical and/or experimental practices to monitor the progression of axonal degeneration in vivo, especially the posterior segment of the optic nerve.

    • Too sweet: Problems of protein glycation in the eye

      2019, Experimental Eye Research
      Citation Excerpt :

      AGE accumulations in the optic nerve, around vessel and in cribriform plates, are also described in streptozotocin-induced diabetic rats, as well as in diabetic patients (Amano et al., 2001; Terai et al., 2012). AGE inhibitors partially reduced the level of glycation in the optic nerve in aged rhesus monkeys and in streptozotocin-induced diabetic rats (Ino-ue et al., 1998; Kiland et al., 2009). Degeneration of the trabecular meshwork leads to pathogenic elevated eye pressure in glaucoma, although the causes remain unknown.

    • The role of advanced glycation end products in retinal ageing and disease

      2009, Biochimica et Biophysica Acta - General Subjects
    • Investigating structural and biochemical correlates of ganglion cell dysfunction in streptozotocin-induced diabetic rats

      2009, Experimental Eye Research
      Citation Excerpt :

      Our findings confirm previous studies that have shown an increase in the percentage of connective tissue and blood vessels (Scott et al., 1986) and a reduction in myelin thickness (Ino-ue et al., 1998a, b), however they do not confirm reports of a reduction in axonal diameter (Ino-ue et al., 1998a, b) in the rat optic nerve. Studies by Ino-ue et al. (1998a, b) demonstrate that changes in the optic nerve were reversed using aminoguanidine (Ino-ue et al., 1998a), an inhibitor of advanced glycation end products (AGEs) and aldose reductase inhibitors (Ino-ue et al., 1998b), which can improve polyol metabolism, suggesting that AGEs/oxidative stress and polyol pathway metabolism may be involved in optic nerve changes. In the present study, alterations in optic nerve structure were not correlated with ganglion cell dysfunction, which argues that the locus of ganglion cell dysfunction after 12 weeks of STZ-induced diabetes might occur at the level of the retina.

    View all citing articles on Scopus
    View full text